Comparison of cardiac troponins i and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: An ARISTOTLE substudy

Clinical Chemistry

Volumn 61, Issue 2, 2015, Pages 368-378

  Hijazi, Ziad ^a   Siegbahn, Agneta ^a   Andersson, Ulrika ^a   Lindahl, Bertil ^a   Granger, Christopher B ^b   Alexander, John H ^b   Atar, Dan ^c   Gersh, Bernard J ^d   Hanna, Michael ^e   Harjola, Veli Pekka ^f   Horowitz, John ^g   Husted, Steen ^h   Hylek, Elaine M ⁱ   Lopes, Renato D ^b   McMurray, John J V ^j   Wallentin, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Mayo Clinic College of Medicine   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY OF ADELAIDE   (Australia)

^h REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

ⁱ BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APIXABAN; BIOLOGICAL MARKER; CYSTATIN C; TROPONIN I; TROPONIN T;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; ASSAY; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHEMICAL ANALYZER; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; THROMBOEMBOLISM; VASCULAR DISEASE; ATRIAL FIBRILLATION; BLOOD; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; MIDDLE AGED; STROKE;

AGED; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; STROKE; TROPONIN I; TROPONIN T;

EID: 84921829695     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2014.226936     Document Type: Article

References (33)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
3. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996; 335:1342-9.
4. Katus HA, Remppis A, Neumann FJ, Scheffold T, Diederich KW, Vinar G, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991;83:902-12.
5. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy. Circulation 2012;125:1605-16.
6. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369-429.
7. Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, et al. High sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circulation 2013;129:625-34.
8. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, et al. High sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol 2014;63:52-61.
9. Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J 2010;31:2197-204.
10. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Rosjo H, Saltyte Benth J, et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J AmColl Cardiol 2013;61:1240-9.
11. Reiter M, Twerenbold R, Reichlin T, Benz B, Haaf P, Meissner J, et al. Early diagnosis of acute myocardial infarction in patients with pre-existing coronary artery disease using more sensitive cardiac troponin assays. Eur Heart J 2012;33:988-97.
12. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation.NEngl JMed2011;365: 981-92.
13. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159:331-9.
14. Apple FS, Collinson PO, IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012;58:54-61.
15. Lindahl B, Eggers KM, Venge P, James S. Evaluation of four sensitive troponin assays for risk assessment in acute coronary syndromes using a new clinically oriented approach for comparison of assays. Clin Chem Lab Med 2013;51:1859-64.
16. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58:1574-81.
17. Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:254-61.
18. Flodin M, Jonsson AS, Hansson LO, Danielsson LA, Larsson A. Evaluation of Gentian cystatin C reagent on Abbott ci8200 and calculation of glomerular filtration rate expressed in mL/min/1.73 m2 from the cystatin C values in mg/L. Scand J Clin Lab Invest 2007;67: 560-7.
19. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the biosite triage BNP assay. Clin Chim Acta 2003;338:107-15.
20. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
21. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
22. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304: 2503-12.
23. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003;108:833-8.
24. James SK, Armstrong P, Barnathan E, Califf R, Lindahl B, Siegbahn A, et al. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003;41:916-24.
25. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC study group. Fragmin during instability in coronary artery disease. N Engl J Med 2000; 343:1139-47.
26. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009;361:2538-47.
27. Eggers KM, Lind L, Venge P, Lindahl B. Factors influencing the 99th percentile of cardiac troponin I evaluated in community-dwelling individuals at 70 and 75 years of age. Clin Chem 2013;59:1068-73.
28. Eggers KM, Venge P, Lindahl B, Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors of mortality in an elderly population. J Am Coll Cardiol 2013;61:1906-13.
29. Francis GS, Tang WH. Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions. Prog Cardiovasc Dis 2004;47:196-206.
30. Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald E. Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI-35. Eur Heart J 2009;30:162-9.
31. Savukoski T, Engstrom E, Engblom J, Ristiniemi N, Wittfooth S, Lindahl B, et al. Troponin-specific autoantibody interference in different cardiac troponin I assay configurations. Clin Chem 2012;58:1040-8.
32. Venge P, Johnston N, Lindahl B, James S. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol 2009;54:1165-72.
33. Venge P, Lindahl B. Cardiac troponin assay classification by both clinical and analytical performance characteristics: a study on outcome prediction. Clin Chem 2013;59:976-81